3 results about "Leonurus heterophyllus" patented technology

This invention belongs to the field of traditional Chinese medicine research technology, specifically relating to a traditional Chinese medicine composition for treating coronary heart disease, its preparation method, and its application. The traditional Chinese medicine composition is made from the following raw materials in parts by weight: Astragalus membranaceus 15-30 parts, Trichosanthes kirilowii 15-30 parts, Inula japonica 9-12 parts, Rubia cordifolia 9-12 parts, Ligusticum chuanxiong 9-12 parts, Salvia miltiorrhiza 15-30 parts, Leonurus japonicus 9-15 parts, Aucklandia lappa 6-9 parts, and Amomum villosum 3-6 parts. This traditional Chinese medicine composition has a good therapeutic effect on inflammatory factors in patients with coronary heart disease exhibiting qi deficiency and phlegm stasis syndrome, and no other adverse reactions such as liver or kidney damage have been observed in the patients.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.

This invention discloses the application of leonurin in the preparation of drugs for reducing serum total bilirubin levels, belonging to the field of traditional Chinese medicine technology. Through the construction of different types of hyperbilirubin animal models, this invention is the first to discover that leonurin can significantly reduce serum total bilirubin levels, and can be used to treat hyperbilirubinemia, alleviate bilirubin elevation caused by cholestasis, and treat acute abnormal bilirubin elevation. Simultaneously, leonurin does not cause abnormalities in liver function indicators such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) during the bilirubin-lowering process, demonstrating good safety. This invention also provides a pharmaceutical composition containing leonurin and its preparation method. This invention provides a new drug option for the treatment of hyperbilirubinemia.